|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
19
|
|
pubmed:dateCreated |
2007-5-8
|
|
pubmed:abstractText |
Patients with mild cognitive impairment (MCI) have increased risk to develop Alzheimer disease (AD). In AD increased brain amyloid burden has been demonstrated in vivo with PET using N-methyl-[(11)C]2-(4'-methylaminophenyl)-6-hydroxybenzothiazole ([(11)C]PIB) as a tracer.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
1526-632X
|
|
pubmed:author |
pubmed-author:AaltoSS,
pubmed-author:BrückAA,
pubmed-author:HelioRR,
pubmed-author:KailajärviMM,
pubmed-author:KemppainenN MNM,
pubmed-author:NågrenKK,
pubmed-author:OikonenVV,
pubmed-author:ParkkolaRR,
pubmed-author:RinneJ OJO,
pubmed-author:ScheininMM,
pubmed-author:ViitanenMM,
pubmed-author:WilsonI AIA
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
8
|
|
pubmed:volume |
68
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1603-6
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:17485647-Aged,
pubmed-meshheading:17485647-Alzheimer Disease,
pubmed-meshheading:17485647-Amnesia,
pubmed-meshheading:17485647-Amyloid beta-Peptides,
pubmed-meshheading:17485647-Benzothiazoles,
pubmed-meshheading:17485647-Brain,
pubmed-meshheading:17485647-Brain Mapping,
pubmed-meshheading:17485647-Cognition Disorders,
pubmed-meshheading:17485647-Female,
pubmed-meshheading:17485647-Humans,
pubmed-meshheading:17485647-Male,
pubmed-meshheading:17485647-Plaque, Amyloid,
pubmed-meshheading:17485647-Positron-Emission Tomography,
pubmed-meshheading:17485647-Predictive Value of Tests
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
PET amyloid ligand [11C]PIB uptake is increased in mild cognitive impairment.
|
|
pubmed:affiliation |
Turku PET Centre, University of Turku, Turku, Finland.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
